Ensoma Gets Pediatric Disease and Orphan Drug Designations for EN-374 in Chronic Granulomatous Disease

Ensoma Gets Pediatric Disease and Orphan Drug Designations for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company focused on developing one-time, in vivo treatments to precisely and durably engineer the hematopoietic system, announced that the U.S. Food and…










